Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 8/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664044 | 0.83 | CYP17A1 (0.66) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL9078342 | 0.83 | CYP17A1 (0.58) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL14837689 | 0.83 | CYP17A1 (0.48) | CYP17A1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL19999188 | 0.81 | CYP19A1 (0.69) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL27428164 | 0.80 | CYP17A1 (0.63) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL1507796 | 0.80 | CYP19A1 (0.68) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL940720 | 0.79 | CYP19A1 (0.70) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL4053811 | 0.78 | CYP17A1 (0.45) | CYP17A1CYP11B1CYP11B2CYP26A1 | |
| SCHEMBL4052241 | 0.78 | CYP17A1 (0.45) | CYP17A1CYP11B1CYP11B2CYP26A1 | |
| SCHEMBL4053809 | 0.78 | CYP17A1 (0.45) | CYP17A1CYP11B1CYP11B2CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-7378433-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-27 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2007-04-19 | — | — | US | disclosed |
| US-7205312-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2005-05-26 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| US-6124330-A | A RETINOIC MIMETIC COMPOUND FOR TREATING A WARM-BLOODED ANIMAL SUFFERING FROM A DISEASE BY AN ABNORMAL PROLIFERATION AND/OR ABNORMAL DIFFERENTIATION OF NORMAL, PRENEOPLASTIC OR NEOPLASTIC CELLS | JANSSEN-CILAG S.A. (FR) | 2000-09-26 | — | — | US | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0907650-A1 | N- 4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049704-A1 | N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-12-31 | — | — | WO | disclosed |
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | disclosed |
| US-5441954-A | Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells | JANSSEN PHARMACEUTICA N. V. (BE) | 1995-08-15 | — | — | US | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5268380-A | Therapy for keratinization in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-07 | — | — | US | disclosed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113378-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | CYP17A1 227/4885CYP11B1 33/4885CYP11B2 31/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | CYP17A1 304/4885CYP11B1 126/4885CYP11B2 222/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | CYP17A1 317/4885CYP11B1 143/4885CYP11B2 242/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | CYP17A1 304/4885CYP11B1 126/4885CYP11B2 222/4885 |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | CYP17A1 227/4885CYP11B1 33/4885CYP11B2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.